Best Practices for Pulmonologists in the Timely Recognition and Comprehensive Management of Fibrosing Interstitial Lung Diseases

Tuesday, February 24, 2026

3:00 AM – 4:00 AM PST simulcast
4:00 AM – 5:00 AM MST
5:00 AM – 6:00 AM CST
6:00 AM – 7:00 AM EST

EARN UP TO 1.0 CME/CNE/AAPA/EACCME CREDITS!

Program Overview

This virtual Summit brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.

Target Audience

This activity is tailored to meet the educational needs of neurologists, psychiatrists – including geriatric psychiatrists, radiologists, neuroradiologists, primary care physicians, emergency physicians, and infusion/triage nurses.

Learning Objectives

Upon the completion of this program, attendees should be able to:

  • Summarize the pathophysiology, clinical presentation, and classification of ARIA (including ARIA-E and ARIA-H) in patients receiving AATs for AD
  • Evaluate guidelines for ARIA monitoring based on signs, symptoms, and imaging findings in patients receiving AATs for AD
  • Communicate effectively with patients and caregivers about individual ARIA risk factors, benefits of AATs, and individualized risk mitigation strategies through SDM principles
  • Collaborate with multidisciplinary team members (including emergency medicine, radiology, and nursing staff) to ensure coordinated ARIA monitoring, recognition, and management across care settings for patients with AD receiving AATs

Joint Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement

Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

Nurses (ANCC) Credit Designation

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.

AAPA Credit Designation Statement – Live

Joint Accreditation Statement

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Disclosure Of Unlabeled Use

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

Disclaimer

Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

Americans With Disabilities Act

Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Release date: May 17, 2025
Expiration date: May 17, 2025
Estimated time to completion: 1 hour